| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Raffit Hassan | Q96951105 |
| P2093 | author name string | Mitchell Ho | |
| P2860 | cites work | Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion | Q24301956 |
| Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers | Q24315965 | ||
| Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors | Q24673454 | ||
| Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells | Q24797540 | ||
| Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation | Q28141319 | ||
| Mesothelin: a new target for immunotherapy | Q28268571 | ||
| Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer | Q28293019 | ||
| Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas | Q30310974 | ||
| Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. | Q30670385 | ||
| Improving antibody affinity by mimicking somatic hypermutation in vitro | Q30724948 | ||
| Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). | Q30781823 | ||
| Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity | Q32140773 | ||
| Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma | Q33233449 | ||
| Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways | Q33814311 | ||
| Mesothelin is not required for normal mouse development or reproduction | Q33895649 | ||
| A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer | Q34254918 | ||
| Identification of novel human CTL epitopes and their agonist epitopes of mesothelin | Q34313298 | ||
| Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma | Q34614377 | ||
| Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients | Q36399737 | ||
| What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update | Q36631062 | ||
| Listeria-based cancer vaccines that segregate immunogenicity from toxicity | Q37535306 | ||
| Localization of mesothelin in epithelial ovarian cancer | Q38441572 | ||
| Mesothelin expression in human lung cancer | Q40164540 | ||
| Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice | Q40245236 | ||
| Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein | Q40401336 | ||
| Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy | Q40496032 | ||
| Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. | Q40531731 | ||
| A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. | Q41494627 | ||
| Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas | Q41619004 | ||
| Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma | Q41636261 | ||
| Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. | Q42808417 | ||
| Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin | Q46511205 | ||
| Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays | Q47960817 | ||
| Application of Mesothelin Immunostaining in Tumor Diagnosis | Q50492362 | ||
| Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts. | Q51790432 | ||
| Value of mesothelin immunostaining in the diagnosis of mesothelioma. | Q54769537 | ||
| Immunotoxin therapy of cancer | Q56454451 | ||
| Mesothelin-family proteins and diagnosis of mesothelioma | Q57297479 | ||
| Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium | Q67743629 | ||
| Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura | Q78841533 | ||
| Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers | Q81038996 | ||
| Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients | Q81753024 | ||
| Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis | Q82279314 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 46-53 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Mesothelin targeted cancer immunotherapy | |
| P478 | volume | 44 |
| Q42333514 | 2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA. |
| Q34180031 | 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy |
| Q24658397 | A binding domain on mesothelin for CA125/MUC16 |
| Q36759405 | A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface |
| Q28392105 | A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas |
| Q35323396 | A novel PET imaging using ⁶⁴Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells |
| Q33634221 | A novel high-affinity human monoclonal antibody to mesothelin. |
| Q46193681 | A single intratracheal instillation of single-walled carbon nanotubes induced early lung fibrosis and subchronic tissue damage in mice |
| Q93005342 | AQP1-Containing Exosomes in Peritoneal Dialysis Effluent As Biomarker of Dialysis Efficiency |
| Q37281460 | Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis |
| Q27015134 | Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin |
| Q35832903 | Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach |
| Q34137322 | Advances in the management of peritoneal mesothelioma |
| Q26852333 | Allogeneic tumor cell vaccines: the promise and limitations in clinical trials |
| Q57821553 | Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models |
| Q36129683 | Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors |
| Q59360557 | Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model |
| Q37224335 | Autoantibodies as biomarkers for ovarian cancer |
| Q39202440 | CAR T-cell therapy for pancreatic cancer. |
| Q33651427 | CCL2 blockade augments cancer immunotherapy |
| Q91740150 | Cancer biomarkers for targeted therapy |
| Q35275675 | Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions |
| Q96817033 | Chd4 choreographs self-antigen expression for central immune tolerance |
| Q64246214 | Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies |
| Q47561397 | Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications |
| Q99565893 | Chimeric antigen receptor T cell therapies for thoracic cancers-challenges and opportunities |
| Q37728639 | Chimeric antigen receptor T cells: a novel therapy for solid tumors |
| Q37892591 | Clinical trials of vaccines for immunotherapy in pancreatic cancer |
| Q44443843 | Connective tissue growth factor and β-catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma |
| Q38761712 | Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy |
| Q89727168 | Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma |
| Q28393560 | Current issues in malignant pleural mesothelioma evaluation and management |
| Q38059514 | Dendritic cell-based immunotherapy in mesothelioma |
| Q42245576 | Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma |
| Q33474388 | Display and selection of scFv antibodies on HEK-293T cells |
| Q34046505 | Driving CAR T-cells forward |
| Q36520143 | Early detection biomarkers for ovarian cancer |
| Q28544295 | Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model |
| Q38828829 | Engineered T cells: the promise and challenges of cancer immunotherapy. |
| Q52641577 | Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer. |
| Q39612474 | Establishment of a cell line from a Japanese patient useful for generating an in vivo model of malignant pleural mesothelioma |
| Q39500230 | Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications. |
| Q38473933 | Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor |
| Q39235922 | Expression of mesothelin in thymic carcinoma and its potential therapeutic significance |
| Q36230681 | Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma |
| Q55257427 | Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding. |
| Q33734661 | Folate receptor alpha, mesothelin and megakaryocyte potentiating factor as potential serum markers of chronic kidney disease |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q34610143 | Gd-labeled microparticles in MRI: in vivo imaging of microparticles after intraperitoneal injection |
| Q28475905 | Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype |
| Q35001563 | HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy |
| Q35793906 | High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. |
| Q37352425 | High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy |
| Q92030344 | Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: Advancing Antibody-Based Cancer Therapies to the Clinic |
| Q38976752 | Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examples. |
| Q36561686 | Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. |
| Q38669273 | Immune Therapy |
| Q35711576 | Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma |
| Q38390104 | Immunotherapy prospects in the treatment of lung cancer and mesothelioma |
| Q37684156 | Immunotoxin Therapy for Lung Cancer |
| Q34771909 | In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice |
| Q46190547 | Increased frequency of circulating invariant natural killer T cells in malignant pleural mesothelioma patients |
| Q33828838 | Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy |
| Q36857863 | Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancer |
| Q35223910 | Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody |
| Q85640217 | Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P |
| Q36075289 | Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer |
| Q37499806 | MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. |
| Q33713506 | MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress |
| Q58541846 | Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives |
| Q83412919 | Malignant pleural mesothelioma |
| Q34513958 | Malignant pleural mesothelioma: an update on diagnosis and treatment options |
| Q38019747 | Malignant pleural mesothelioma: from the bench to the bedside. |
| Q33413791 | Mammalian cell display for antibody engineering |
| Q41992584 | Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes |
| Q34167021 | Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma |
| Q47153393 | Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma |
| Q35219548 | Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression |
| Q37339008 | Mesothelin expression and survival outcomes in triple receptor negative breast cancer |
| Q34703865 | Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival |
| Q37621377 | Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma |
| Q37139387 | Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. |
| Q34847859 | Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS- regulatory T cells. |
| Q37134884 | Mesothelin, a novel immunotherapy target for triple negative breast cancer |
| Q35815380 | Mesothelin-targeted agents in clinical trials and in preclinical development |
| Q34984956 | Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts |
| Q92825517 | Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor |
| Q93090675 | Modular Antigen-Specific T-cell Biofactories for Calibrated In Vivo Synthesis of Engineered Proteins |
| Q42548610 | Modulating mesothelin shedding to improve therapy |
| Q35385267 | Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion |
| Q37269020 | Near infrared photoimmunotherapy with an anti-mesothelin antibody. |
| Q52581757 | New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma. |
| Q28547381 | New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma |
| Q52672888 | New horizons from immunotherapy in malignant pleural mesothelioma. |
| Q34331993 | New roads open up for implementing immunotherapy in mesothelioma |
| Q33834277 | Non-invasive tumor detection in small animals using novel functional Pluronic nanomicelles conjugated with anti-mesothelin antibody. |
| Q35049589 | Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice |
| Q92957225 | Novel single-chain variant of antibody against mesothelin established by phage library |
| Q54965295 | Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. |
| Q35034010 | Past, present and future targets for immunotherapy in ovarian cancer |
| Q34676443 | Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers |
| Q51444618 | Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil. |
| Q37861220 | Potential targets for pancreatic cancer immunotherapeutics |
| Q39405625 | Quantitative Imaging Approaches to Study the CAR Immunological Synapse. |
| Q37337213 | Quantum dot-based nanoprobes for in vivo targeted imaging |
| Q35750271 | Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer |
| Q35479808 | Rapid generation of in vitro multicellular spheroids for the study of monoclonal antibody therapy |
| Q27024368 | Role of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer |
| Q36808757 | Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. |
| Q26860736 | Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis |
| Q26853171 | Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer |
| Q37762833 | Surgery for malignant pleural mesothelioma |
| Q35768107 | Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma |
| Q64387609 | Synergistic Effect of a Mesothelin Targeted Thorium-227 Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models |
| Q37260408 | Systemic treatments for mesothelioma: standard and novel |
| Q33625651 | Targeted drug delivery in pancreatic cancer |
| Q50033731 | The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective |
| Q21198791 | The detection, treatment, and biology of epithelial ovarian cancer |
| Q27314606 | The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy |
| Q52641562 | The development of CAR design for tumor CAR-T cell therapy. |
| Q35185032 | The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors. |
| Q34103645 | The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells |
| Q47096103 | The immunopeptidomic landscape of ovarian carcinomas. |
| Q27012919 | The impact of transposable elements in genome evolution and genetic instability and their implications in various diseases |
| Q36745522 | The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin |
| Q36597831 | The role of mesothelin in tumor progression and targeted therapy |
| Q55483367 | Therapeutic antibodies for the treatment of pancreatic cancer. |
| Q64113812 | Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment |
| Q35815574 | Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma |
| Q37972865 | Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies |
| Q55658029 | Trial watch: Chemotherapy with immunogenic cell death inducers. |
| Q28740545 | Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer |
| Q36665335 | What is recent in pancreatic cancer immunotherapy? |
Search more.